[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"postprandial-glucose\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:postprandial-glucose":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,70,113,149,172],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100634872","effect-of-circadian-timing-of-a-standardized-meal-on-postprandial-glucose-response-in-healthy-adults-100634872",false,"NCT07545330","Effect of Circadian Timing of a Standardized Meal on Postprandial Glucose Response in Healthy Adults","Inclusion Criteria:\n\n* Healthy adults aged 18 years and older\n* Able and willing to provide informed consent\n* Able to comply with study procedures\n\nExclusion Criteria:\n\n* Diagnosis of diabetes or any metabolic disorder affecting glucose regulation\n* Use of any medications\n* Pregnant or breastfeeding women\n* Night shift workers or individuals with irregular sleep patterns",true,"ALL","18 Years",{"count":19,"type":20},32,"ESTIMATED","INTERVENTIONAL",[23],"NA","This randomized crossover study aims to investigate the effect of circadian timing of a standardized meal (morning versus evening consumption) on postprandial glucose response in healthy adults. Postprandial glucose will be assessed using the incremental area under the curve (iAUC) over 120 minutes.",[26,27,28],"Meal Timing","Postprandial Glucose","Glycemic Response to Feeding in Healthy Participants","NOT_YET_RECRUITING","2026-04-16",{"date":32,"type":33},"2026-04-22","ACTUAL",{"date":35,"type":20},"2026-04-15",{"date":37,"type":20},"2026-05-30",{"name":39,"class":40},"King Faisal University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":41},"100626339","exercise-timing-and-postprandial-glucose-responses-100626339","NCT07434349","Exercise Timing and Postprandial Glucose Responses","Exercise Timing and Postprandial Glucose Responses in Healthy Adults","ExTime-Glu","Inclusion Criteria:\n\n* Age 18 to 35 years\n* Body mass index 18.5 to 24.9 kg per square meter\n* Able to complete 45 minutes of continuous running at an intensity corresponding to 75 to 85 percent of maximal heart rate without stopping\n* Engages in regular endurance-type physical activity\n* Habitual waking times are compatible with the fixed breakfast time of 08:00\n* Willing and able to comply with all study procedures, including standardized meals, exercise sessions, behavioral restrictions, and continuous glucose monitoring\n* For female participants: non-pregnant and using stable hormonal contraception for at least 3 months\n\nExclusion Criteria:\n\n* Acute or chronic illness\n* Metabolic disorders or conditions associated with altered glucose or lipid metabolism\n* Use of medications known to interfere with glucose metabolism or study outcomes\n* Intolerance or allergy to components of the standardized study diets\n* Pregnancy or breastfeeding\n* Body mass index greater than or equal to 25 kg per square meter\n* Current or past eating disorder, or any medical condition or medication that could affect appetite regulation, glucose regulation, or make vigorous endurance exercise unsafe\n* Current smoking or use of nicotine-containing products","35 Years",{"count":52,"type":20},30,[23],"This interventional crossover study examines the effect of exercise timing relative to meal intake on postprandial glucose responses in healthy, physically active young adults. Participants complete five experimental conditions involving endurance exercise performed before or after breakfast or dinner, as well as a non-exercise control condition, while wearing a continuous glucose monitoring device.\n\nPostprandial glucose responses are assessed for the three consecutive meals following each exercise session. Following morning exercise, outcomes are assessed after breakfast, lunch, and dinner on the same day. Following evening exercise, outcomes are assessed after dinner on the same day and after breakfast and lunch on the subsequent day. All meals are standardized and consumed at fixed clock times.",[56,27],"Exercise Timing",[56,27,58,59,60],"Continuous Glucose Monitoring","Endurance Exercise","Glycemic Response","RECRUITING",{"date":63,"type":33},"2026-04-20",{"date":65,"type":33},"2026-04-01",{"date":67,"type":20},"2026-08",{"name":69,"class":40},"Technical University of Munich",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":15,"sex":16,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":41},"100606449","ultra-processed-food-reducing-intervention-and-continuous-glucose-monitoring-100606449","NCT07175701","Ultra-processed Food-reducing Intervention and Continuous Glucose Monitoring","Effects of Ultra-processed Food Reduction Intervention on Postprandial Glucose and Glycemic Variability in Korean Young Adults: Study Protocol for the ULTRA-CGM Randomized Controlled Trial","ULTRA-CGM","Inclusion Criteria:\n\n1. Korean adults aged 20-39 years\n2. Not currently pregnant\n3. No personal history of diabetes or other glucose-related conditions\n4. Consume ≥25% of daily energy intake from UPFs, as assessed by an online, self-administered semi-quantitative screening food frequency questionnaire (FFQ)\n5. No restriction on wearing a CGM device\n6. No increased risk of bleeding\n7. No prior adverse reaction to CGM devices\n8. Willingness to participate in follow-up assessments\n\nExclusion Criteria:\n\n1. Unable to maintain continuous follow-up during the study period (e.g., due to special plans such as traveling)\n2. Planning to follow a special or restrictive diet (e.g., for weight loss) during the study period","20 Years","39 Years",{"count":81,"type":20},50,[23],"The goal of this trial is to investigate whether reduction in ultra-processed food intake through dietary counseling and education can improve postprandial glucose responses and glycemic variability compared with a usual diet in young, healthy Korean adults aged 20-30 years. The main questions it aims to answer are:\n\n\\- Does reducing ultra-processed food intake, while maintaining total energy intake and usual lifestyle behaviors, improve postprandial glucose and lower glycemic variability in healthy adults without diabetes?\n\nParticipants will:\n\n* Undergo the 10-day pre-intervention monitoring period, during which each participant will wear a continuous glucose monitoring (CGM) device and concurrently report their daily dietary intakes (all food and beverage consumption) and other lifestyle behaviors (sleep, smoking, physical activity)\n* After the 10-day pre-intervention monitoring period, participants will be randomized to either intervention or control group\n* Intervention group: Participants will visit the research site to receive dietitian-led one-on-one nutrition education and personalized dietary counseling targeting reduction of ultra-processed food intake. Personalized diet counseling will be provided by study dietitian based on participant's records of dietary intakes during the 10-day pre-intervention monitoring period.\n* Control group: Participants will receive dietitian-led nutrition education and personalized dietary counseling based on the national dietary guidelines.\n* After the intervention, participants will undergo the 10-day post-intervention monitoring period, during which participants will wear a new CGM device for an additional 10 days and continue daily reporting of dietary intakes (all food and beverage consumptions) and lifestyle behaviors (sleep, smoking, physical activity).",[27,85,86],"Glucose Levels","Hyperglycemias",[88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103],"ultra-processed food","continuous glucose monitoring","processed food","glucose","glycemic variability","glycemic control","hyperglycemia","glucose intolerance","Food Additives","flavoring agents","sweetening agents","non-nutritive sweeteners","nutritive sweeteners","high fructose corn syrup","food coloring agents","food preservatives","2026-04-13",{"date":106,"type":33},"2026-04-17",{"date":108,"type":33},"2025-10-11",{"date":110,"type":20},"2026-08-31",{"name":112,"class":40},"Korea University",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":21,"phases":123,"briefSummary":124,"conditions":125,"keywords":131,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":41},"100614320","impact-of-dietary-fat-and-menstrual-cycle-phases-in-type-1-diabetes-100614320","NCT07278063","Impact of Dietary Fat and Menstrual Cycle Phases in Type 1 Diabetes","Effect of Gender and Meal Composition on the Postprandial Glycemic Response in People With Type 1 Diabetes: Impact of Fat Content and Menstrual Cycle Phases","DIABETEXX\u002F3","Inclusion Criteria:\n\n* Patients with a confirmed diagnosis of type 1 diabetes mellitus for more than 2 years, in treatment with AHCL (Advanced Hybrid Closed Loop) system treatment for at least 6 months.\n* Both sexes.\n* Metabolic control with HbA1c \\\u003C8%.\n* BMI between 18.5 and 29.99 (normal weight to overweight).\n* For women: regular menstrual cycles (21-35 days in length with variation between cycles of \\\u003C4 days) and no use of hormonal contraceptive treatment.\n\nExclusion Criteria:\n\n* Diagnosis of diabetic gastroparesis.\n* Presence of hypogonadism, anovulation, hyperandrogenism, hyperprolactinemia, pregnancy, or decompensated chronic diseases.\n* Use of oral medications that alter glucose metabolism.","45 Years",{"count":81,"type":20},[23],"This clinical trial aims to evaluate how variations in dietary fat content and hormonal status influence postprandial glycemic response in individuals with type 1 diabetes (T1D), with a special focus on women. The main objective is to clarify the impact of both factors individually and their interaction, which could inform more personalized strategies for insulin adjustment, optimizing glycemic control, and improving patient outcomes.\n\nThe main objective is to investigate the effects of low-fat versus high-fat meals, sex, menstrual cycle phases, and their interaction on postprandial glycemic control in adults with T1D treated with advanced hybrid closed-loop (AHCL) insulin delivery systems.\n\nSpecifically, the study will:\n\n* Compare postprandial glycemic responses after standardized low and high-fat meals in men and women with T1D.\n* Assess the differences in postprandial glycemic responses between early follicular and late luteal phases in women, using standardized meals with low and high fat content.\n* Identify sex-related differences in glycemic response after equivalent meals.\n\nThis research addresses the unmet clinical need for precise, tailored postprandial insulin dosing recommendations, especially among women whose insulin sensitivity fluctuates with menstrual phases. The results may contribute to sex-specific predictive models in AHCL systems, reducing acute complications and improving overall quality of life.\n\nThis is a randomized controlled crossover trial in which each participant serves as her\u002Fhis own control. Fifty adults will be enrolled: 25 women and 25 men. Women will undergo four mixed-meal tests in random order:\n\n* low-fat given during the early follicular phase,\n* high-fat given during the early follicular phase,\n* low-fat given during the late luteal phase,\n* high-fat given during the late luteal phase. The menstrual phase will be confirmed with home-based hormonal monitoring devices that function with urine sample and use a single-use test wand (MIRA system).\n\nMen will complete two mixed-meal tests (low-fat and high-fat), in randomized order.\n\nAll meals will be standardized for carbohydrate content and matched in other macronutrients, except for fat (with a 30-40g difference), administered after an 8-hour fast. The day of the mixed meal test, AHCL systems will be switched from automatic to manual mode just before eating to standardize the prandial insulin dose and to avoid differences in insulin infusion rates in the postprandial state due to algorithm compensations. Continuous glucose monitoring (CGM) and hourly capillary glucose testing will measure the postprandial response. Additional fasting blood samples will assess metabolic, hormonal, and lipid markers. Optional gastric emptying studies may be performed to exclude confounding gastroparesis in selected patients.\n\nParticipants will be recruited from the endocrinology outpatient unit of La Fe Polytechnic University Hospital . The projected recruitment period is from December 2025 to July 2027, with mixed-meal tests and data collection occurring between January 2026 and December 2027. Women are expected to complete the protocol in 6 weeks (4 tests), while men will require about 2 weeks (2 tests).\n\nAt baseline, participants will undergo blood tests to rule out endocrine disorders and confirm sex hormone status. Women participating in the study will use the MIRA home device to monitor their hormonal levels, allowing them to accurately determine and record the phases of their menstrual cycle as part of the study protocol. During meal tests, CGM (Freestyle Libre 3) will be used uniformly among subjects.\n\nThe study dependent variables will be the following:\n\n* Postprandial glucose area under the curve - AUC\\_PG\\_5h\n* Mean glucose level - MG\n* Continuous glucose monitoring metrics - TIR, TAR, TBR\n* Postprandial glucose standard deviation - SD\n* Postprandial glucose coefficient of variation - CV\n* Mean amplitude of glycemic excursions - MAGE\n* Mean of daily differences (MODD)\n\nIndependent variables are\n\n* Type of food: Meals with either low or high fat content.\n* Sex and Hormonal status: men; women during the early follicular phase; women during the late luteal phase.\n\nIf successful, this study will inform the development of more sophisticated, individualized insulin dosing algorithms and AHCL system improvements, especially for women with T1D. Results may lead to more effective management strategies, reduced GV, lower incidence of complications, and increased quality of life. Insights may directly support the personalization of diabetes care and improve gender equity in treatment standards.",[126,127,128,129,130,27],"Type 1 Diabetes Mellitus","Glycemic Variability","Sex Characteristics","Menstrual Cycle","Dietary Fat",[132,92,133,134,135,136,137,89,138,139],"Type 1 diabetes","advanced hybrid closed-loop systems","menstrual cycle","postprandial glucose","dietary fat","insulin sensitivity","mixed-meal test","personalized insulin therapy","2026-03-20",{"date":142,"type":33},"2026-03-23",{"date":144,"type":20},"2026-05",{"date":146,"type":20},"2028-04",{"name":148,"class":40},"Instituto de Investigacion Sanitaria La Fe",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":21,"phases":159,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":171,"locationsCount":41},"100627351","effect-of-a-high-protein-high-fiber-pre-fast-meal-on-satiety-and-glycemic-profiles-during-fasting-100627351","NCT07447505","Effect of a High-Protein, High-Fiber Pre-Fast Meal on Satiety and Glycemic Profiles During Fasting","Effect of a High-Protein, High-Fiber Pre-Fast Meal on Satiety and Glycemic Profiles During Fasting: A Randomized Crossover Study","FAST-SAT","Inclusion Criteria:\n\n* Adults aged 18 years and older\n* Willingness to comply with study procedures, including fasting and continuous glucose monitoring\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Diagnosed diabetes mellitus or known metabolic disease\n* History of cardiovascular, gastrointestinal, or endocrine disorders that may affect study outcomes\n* Use of medications known to affect glucose metabolism or appetite\n* Pregnancy or lactation\n* Known allergy or intolerance to any study meal components (oats, dairy, peanuts, nuts, cranberries)",{"count":158,"type":20},38,[23],"This randomized crossover study investigates the effect of consuming a high-protein, high-fiber pre-fast meal on subjective satiety and glycemic responses during fasting hours in healthy adults. Participants will complete two dietary conditions in a randomized order: a standardized high-protein, high-fiber pre-fast meal and a low-protein, low-fiber pre-fast meal guided by dietary instructions. Each condition will be followed for two consecutive days and separated by a three-day washout period. Outcomes include subjective appetite sensations during fasting hours, glycemic profiles assessed using continuous glucose monitoring (CGM), and exploratory analyses examining the association between glucose dynamics and appetite sensations.",[162,163,164,27],"Glycemic Response; Satiety","Fasting, Time Restricted","Dietary Intervention","2026-03-10",{"date":167,"type":33},"2026-03-12",{"date":169,"type":33},"2026-02-23",{"date":142,"type":20},{"name":39,"class":40},{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":15,"sex":16,"minAge":78,"maxAge":179,"enrollmentInfo":180,"targetDuration":4,"studyType":21,"phases":182,"briefSummary":183,"conditions":184,"keywords":186,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":41},"100600706","a-clinical-trial-to-investigate-the-acute-effect-of-bragg-apple-cider-vinegar-supplement-on-blood-glucose-control-in-a-healthy-adult-population-100600706","NCT07100977","A Clinical Trial to Investigate the Acute Effect of Bragg Apple Cider Vinegar Supplement on Blood Glucose Control in a Healthy Adult Population","A Randomized, Double-blind, Placebo-controlled, Cross-over Clinical Trial to Investigate the Efficacy of Bragg Apple Cider Vinegar Supplement on Blood Glucose Control in a Healthy Adult Population","Inclusion Criteria:\n\n1. Males and females 20 - 65 years of age, inclusive\n2. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening\n\n   Or,\n\n   Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:\n   * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)\n   * Double-barrier method\n   * Intrauterine devices\n   * Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s)\n   * Vasectomy of partner at least 6 months prior to screening\n   * Abstinence and agrees to use contraception if planning on becoming sexually active during the study\n3. Subjects with elevated fasting glucose \\> 5.6 mmol\u002FL (\\> 100 mg\u002FdL) and \\\u003C 7.0 mmol\u002FL (\\\u003C 126 mg\u002FdL) and\u002For elevated HbA1c (6.0-6.4%) and two or more of the other following markers associated with metabolic syndrome at screening:\n\n   1. Abdominal obesity: waist circumference \\> 102 cm (40 inches) in men and \\> 88 cm (35 inches) in women\n   2. Hypertension: systolic blood pressure \\> 130 mmHg or diastolic blood pressure \\> 85 mmHg\n   3. Elevated TG: \\> 150 mg\u002FdL (1.7 mmol\u002FL)\n   4. Low HDL-C: \\\u003C 40 mg\u002FdL (1.03 mmol\u002FL) in men and \\\u003C 50 mg\u002FdL (1.29 mmol\u002FL) in women\n4. Stable body weight defined as a \\\u003C5% change in body weight in the three months prior to baseline, as assessed by the Qualified Investigator (QI)\n5. Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study\n6. Agrees to comply with dietary guidelines and study requirements prior to in-clinic visits\n7. Provided voluntary, written, informed consent to participate in the study\n8. Otherwise healthy as determined by medical history and laboratory results as assessed by the Qualified Investigator (QI).\n\nExclusion Criteria:\n\n1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study\n2. Allergy, sensitivity or intolerance, preventing consumption of investigational product, placebo, or standardized meal\n3. Poor venous access as assessed by the QI\n4. Current use of prescribed and\u002For OTC medications, supplements, and\u002For consumption of food\u002Fdrinks that may impact the glucose metabolism or efficacy of the investigational product (Sections 7.3.1 and 7.3.2)\n5. Unstable metabolic disease or chronic diseases as assessed by the QI\n6. Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI\n7. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n8. Type I or Type II diabetes\n9. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis\n10. History of or current diagnosis with kidney and\u002For liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months\n11. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n12. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI\n13. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable\n14. Individuals with an autoimmune disease or are immune compromised as assessed by the QI\n15. Self-reported confirmation of a HIV-, Hepatitis B- and\u002For C-positive diagnosis as assessed by the QI\n16. Self-reported confirmation of blood\u002Fbleeding disorders as assessed by the QI\n17. Chronic inhalation or edible use of cannabinoid products (\\>1 time\u002Fmonth). Occasional users must agree to abstain from use while participating in the study\n18. Regular use of tobacco or nicotine products in the past six months, as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period\n19. Alcohol intake average of \\>2 standard drinks per day as assessed by the QI\n20. Alcohol or drug abuse within the last 12 months\n21. Clinically significant abnormal laboratory results at screening as assessed by the QI\n22. Blood donation or blood loss between 101 mL to 449 mL within 30 days prior to screening; blood donation of more than 450 mL within 90 days prior to screening; blood donation during the study or a planned donation within 3 months of the last study visit; or plasma donation (e.g., plasmapheresis) within 15 days prior to screening\n23. Participation in other clinical research studies 30 days prior to baseline as assessed by the QI\n24. Individuals who are unable to give informed consent\n25. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant","65 Years",{"count":181,"type":20},24,[23],"The goal of this clinical trial is to evaluate the efficacy of a Bragg ACV supplement on postprandial glucose excursion compared to a placebo following a standardized acute carbohydrate load.\n\nParticipants will be asked to consume an apple cider vinegar supplement 10 minutes prior to a standardized meal.",[27,185],"Blood Glucose Concentration",[187,188,189],"Apple Cider Vinegar","Apple Cider Vinegar Supplement","Bragg Live Food Products","2026-01-08",{"date":192,"type":33},"2026-01-09",{"date":194,"type":20},"2026-01",{"date":196,"type":20},"2026-02",{"name":189,"class":198},"INDUSTRY"]